Grey Matter is redefining how we treat Alzheimer’s and other neurological disorders through the novel application of focused ultrasound. The company’s non-invasive deep brain stimulation technology enables precise neuromodulation anywhere in the brain – without the need for surgery or real-time imaging. This unique approach opens the door to more accessible and potentially chronic treatments, including in outpatient and at-home settings. By harnessing a modality originally developed by leading researchers at Sunnybrook Research Institute, Grey Matter is pioneering a safer, more scalable path forward for patients living with neurodegenerative diseases.